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Background
Adoptive T-cell therapy (ACT) with tumor infiltrating
lymphocytes (TILs) is a personalized treatment for cancer
defined as the infusion of T cells isolated from the
patient’s own tumor tissue after ex vivo activation and sev-
eral rounds of expansion. This treatment has achieved
impressive clinical results in several single institution
phase I/II clinical trials performed outside Europe, and
holds the promise to enter the mainstream of standard
melanoma care in the near future. However, although
transient, the toxicities associated with high-dose IL-2
classically administered together with TILs are severe and
recent data have questioned its use.
Material and methods
In an ongoing phase I/II study, we have enrolled patients
with progressive metastatic melanoma. TILs infusion was
preceded by standard lymphodepleting chemotherapy but
followed by low-dose subcutaneous IL-2 for 14 days or by
an intravenous intermediate dose IL-2 decrescendo
regimen.
Results
The lower doses of IL-2 considerably decreased the toxi-
city of the treatment while PET-CT imaging showed a
preserved objective response rate of 48% including long-
lasting complete responders. The absolute number of
tumour specific T-cells infused was significantly asso-
ciated to clinical response, with induction of peripheral
tumour reactive T cells. To characterize the fate of TILs
after infusion, we performed a longitudinal analysis of
bulk tumor-reactive T cells from in vitro cultured TILs
and found durable persistent T-cells after up to 1.5 years
after infusion. Extensive analysis of disease relapse in two
patients revealed multiple potential mechanisms of
tumor recurrence, linked either to tumor-changes or
immune response decline.
Conclusion
Despite its clinical efficacy, with impressive response rates
and a significant fraction of long surviving complete
responders, the implementation of TIL based ACT into
current practice has been severely hampered by the tech-
nical complexity of cell production, the toxicity profile
demanding treatment at specialize cancer centers, and
lack of investment from the pharmaceutical industry. Next
step should be a pivotal phase III trial in melanoma which
is required for regulatory approval. Further improvement
of the therapy could also be pursued through combination
treatment.
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